Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1275-1280

  Heinemann, Volker ^a   Bosse, Daniel ^a   Jehn, Ulrich ^a   Kähny, Brigitte ^a   Wachholz, Kirsten ^a   Debus, Alexander ^a   Scholz, Priska ^a   Kolb, Hans Jochem ^a   Wilmanns, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CRITICAL ILLNESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030950678     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1275     Document Type: Article

References (37)

1. Adler-Moore, J. P., S. M. Chiang, A. Satorius, D. Guerra, B. McAndrews, E. J. McManus, and R. T. Proffitt. 1991. Treatment of murine candidosis and cryptococcosis with a multilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B):63-71.
2. Adler-Moore, J. P., and R. T. Proffitt. 1993. Development, characterization, efficacy and mechanism of action of AmBisome, a unilamellar formulation of amphotericin B. J. Liposome Res. 3:429-450.
3. Anaissie, E., V. Paetznick, R. Proffitt, J. Adler-Moore, and G. P. Bodey. 1991. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10:665-668.
4. Bindschadler, D. D., and J. E. Bennett. 1969. A pharmacologic guide to the clinical use of amphotericin B. J. Infect. Dis. 120:427-436.
5. Burch, P. A., J. E. Karp, W. G. Merz, J. E. Kuhlman, and E. K. Fishman. 1987. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5:1985-1993.
6. Chopra, R., S. Blair, J. Strang, P. Cervi, K. G. Patterson, and A. H. Goldstone. 1991. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J. Antimicrob. Chemother. 28(Suppl. B):93-104.
7. Christiansen, K. J., E. M. Bernard, J. W. M. Gold, and D. Armstrong. 1985. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152: 1037-1043.
8. Colette, N., P. van der Auwera, A. Pascual Lopez, C. Heymans, and F. Meunier. 1989. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob. Agents Chemother. 33:362-368.
9. Feldman, H. A., and J. D. Hamilton. 1973. Ampholericin B therapy in an anephric patient. Antimicrob. Agents Chemother. 4:302-330.
10. Fields, B. T., J. H. Bates, and R. S. Abernathy. 1970. Amphotericin B serum concentrations during therapy. Appl. Microbiol. 19:955-959.
11. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
12. Gondal, J. A., R. P. Swartz, and A. Rahman. 1989. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544-1548.
13. Gray, A., and J. Morgan. 1991. Liposomes in hematology. Blood Rev. 5:258-271.
14. Gregoriadis, G. 1991. Overview of liposomes. J. Antimicrob. Chemother. 28(Suppl. B):39-48.
15. Gregoriadis, G., and A. T. Florence. 1993. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 45:15-28.
16. Heinemann, V., U. Jehn, P. Scholz, B. Gleixner, W. Möhrle, K. Wachholz, and H.-J. Kolb. 1993. Pharmacokinetics and clinical results. Bone Marrow Transplant. 12(Suppl.):147-148.
17. Heinemann, V., and U. Jehn. 1994. New approaches to amphotericin B treatment: pharmacokinetics and tissue distribution of liposomal amphotericin B (AmBisome) vs other lipid based formulations. Onkologie 17(Suppl.): 58.
18. Heinemann, V., A. Debus, B. Kähny, K. Wachholz, and U. Jehn. 1994. Vergleichende Untersuchung zur Pharmakokinetik verschiedener Amphotericin B-Präparationen, p. 332-333. In Jäger (ed.), HIV-Medizin: Möglichkeiten der individualisierten Therapie. ECOMED Verlag, Landsberg/Lech, Germany.
19. Heinzel, G., R. Woloszak, and P. Thomann. 1993. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart, Germany.
20. Humphreys, H., D. A. Oliver, R. Winter, and D. W. Warnock. 1994. Liposomal amphotericin B and continuous venous-venous haemofiltration. J. Antimicrob. Chemother. 33:1070.
21. Janknegt, R., S. de Marie, A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-291.
22. Joly, V., L. Saint-Julien, C. Carbon, and P. Yeni. 1990. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J. Pharmacol. Exp. Ther. 255:17-22.
23. Khoo, S. H., J. Bond, and D. W. Denning. 1994. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 33:203-213.
24. Lopez-Berestein, G., R. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E. M. Hersh, and R. Juliano. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147:939-945.
25. Lopez-Berestein, G. 1987. Liposomes as carriers of antimicrobial agents. Antimicrob. Agents Chemother. 31:657-678.
26. Lopez-Berestein, G., G. P. Bodey, V. Fainstein, M. Keating, L. S. Frankel, B. Zeluff, et al. 1989. Treatment of systemic fungal infections with liposomal amphotericin B. Arch. Intern. Med. 149:2533-2536.
27. Mehta, R., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells hut not to mammalian cells Biochim. Biophys. Acta 770:230-234.
28. Meunier, F., H. G. Prentice, and O. Ringden. 1991. Liposonial amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl. B):83-91.
29. Patterson, T., and V. T. Andriole. 1989. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur. J. Cancer Clin. Oncol. 25(Suppl. 2):63-68.
30. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
31. Sculier, J. P., A. Coune, F. Meunier, C. Brassine, C. Laduron, et al. 1988. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 24:527-538.
32. Szoka, F. C., D. Milholland, and M. Barza. 1987. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:421-429.
33. Tollemar, J., O. Ringden, and G. Tyden. 1990. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin. Transplant. 4:167-175.
34. Tollemar, J., and O. Ringden. 1992. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome). Drug Invest. 4:232-238.
35. Van Etten, E. W. M., C. Van den Heuvel-de Groot, and I. A. J. M. Bakker Woudenberg. 1993. Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. J. Antimicrob. Chemother. 32:723-739.
36. Van Etten, E. W. M., M. Otte-Lambillion, W. van Vianen, M. T. ten Kate, and I. A. J. M. Bakker-Woudenberg. 1995. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chemother. 35:509-519.
37. Wasan, K., V. B. Grossie, and G. Lopez-Berestein. 1994. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 38:2224-2226.